NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announced that top-line data results from its Phase 2a ...

Entrada Therapeutics (NASDAQ:TRDA) used a presentation at Guggenheim’s 2026 Emerging Outlook Biotech Summit to outline its pipeline focus on intracellular therapeutics and to preview multiple clinical ...

NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announced that top-line data results from its Phase 2a SYNAPSE-C ...

PTC Therapeutics, Inc.  announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarnatm (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy ...

Loe expects Satellos to generate negative $25.0-million in Adjusted EBITDA on nil revenue in fiscal 2025, deteriorating to ...

We were honored to receive the 2025 Clinical Trials Arena R&D Excellence Award in the Precision Endocrine Therapy category, reflecting growing awareness of the utility of (Z)-endoxifen across oncology ...

At a meeting with Archpriest Alexander Tkachenko, chairman of the board of the Circle of Kindness Foundation that supports ...

UCP Merchant Medicine, the leading provider of consulting services and AI technology for Urgent Care, announced today new research published by The Journal of Urgent Care Medicine detailing the ...

The Pegg family set up ‘George’s Journey’ family fund with Muscular Dystrophy UK in 2015, inspired by their son George, who ...

SAT-3247, an oral therapy aimed at restoring muscle repair, is now in Phase 2 testing in children with DMD.

Roche’s phase III FENtrepid study of fenebrutinib meets its primary endpoint of non-inferiority compared to Ocrevus in reducing disability progression in patients with PPMS ...